Levodopa strengths and weaknesses
- 1 February 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (suppl_1) , S19-S32
- https://doi.org/10.1212/wnl.58.suppl_1.s19
Abstract
Despite clinical experience with levodopa for more than three decades, the role of this agent in the treatment of Parkinson’s disease (PD) has not been well defined. Clearly the most effective antiparkinsonian drug, levodopa, is associated with emergence of motor complications, particularly fluctuations and dyskinesias, as well as other side effects. In addition to these limitations, there is an ongoing debate about the potential neurotoxic effects of levodopa, suggested by some in vitro studies. However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management.Keywords
This publication has 129 references indexed in Scilit:
- Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnoverAnnals of Neurology, 2001
- The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Treatment of Parkinson's disease should begin with a dopamine agonistMovement Disorders, 1999
- EntacaponeDrugs, 1999
- Levodopa-Induced NeurotoxicityCNS Drugs, 1997
- Malignant melanoma and levodopa: Is there a relationship? Two new cases and a review of the literatureJournal of the American Academy of Dermatology, 1997
- Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanismsAnnals of Neurology, 1994
- Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long‐term dyskinesia reductionMovement Disorders, 1994
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's DiseaseBasic & Clinical Pharmacology & Toxicology, 1990